{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:50:24Z","timestamp":1791175824948,"version":"4.1.0"},"reference-count":64,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"32","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Society of Clinical Oncology Educational Book"],"published-print":{"date-parts":[[2012,6]]},"abstract":"<jats:sec><jats:title>Overview:<\/jats:title><jats:p> The molecular biology of the BCR-ABL1-negative chronic myeloproliferative neoplasms (MPNs) has witnessed unprecedented advances since the discovery of the acquired JAK2 V617F mutation in 2005. Despite the high prevalence of JAK2 V617F in polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), and the common finding of dysregulated JAK-STAT signaling in these disorders, it is now appreciated that MPN pathogenesis can reflect the acquisition of multiple genetic mutations that alter several biologic pathways, including epigenetic control of gene expression. Although certain gene mutations are identified at higher frequencies with disease evolution to the blast phase, MPN initiation and progression are not explained by a single, temporal pattern of clonal changes. A complex interplay between acquired molecular abnormalities and host genetic background, in addition to the type and allelic burden of mutations, contributes to the phenotypic heterogeneity of MPNs. At the population level, an inherited predisposition to developing MPNs is linked to a relatively common JAK2-associated haplotype (referred to as \u201846\/1\u2019), but it exhibits a relatively low penetrance. This review details the current state of knowledge of the molecular genetics of the classic MPNs PV, ET, and PMF and discusses the clinical implications of these findings. <\/jats:p><\/jats:sec>","DOI":"10.14694\/edbook_am.2012.32.85","type":"journal-article","created":{"date-parts":[[2020,2,7]],"date-time":"2020-02-07T18:55:56Z","timestamp":1581101756000},"page":"411-418","source":"Crossref","is-referenced-by-count":4,"title":["Insights into the Molecular Genetics of Myeloproliferative Neoplasms"],"prefix":"10.1200","author":[{"given":"Huong (Marie)","family":"Nguyen","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, Stanford University School of Medicine\/Stanford Cancer Institute, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Gotlib","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Medicine, Stanford University School of Medicine\/Stanford Cancer Institute, Stanford, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V6.4.372.372"},{"key":"B3","doi-asserted-by":"crossref","unstructured":"Adamson JW, Fialkow PJ, Murphy S, et al. Polycythemia vera: Stem-cell and probable clonal origin of the disease. N Engl J Med. 1976;295:913-916.","DOI":"10.1056\/NEJM197610212951702"},{"key":"B4","doi-asserted-by":"crossref","unstructured":"Prchal JF, Axelrad AA. Bone-marrow responses in polycythemia vera. N Engl J Med. 1974;290:1382.","DOI":"10.1056\/NEJM197406132902419"},{"key":"B5","doi-asserted-by":"crossref","unstructured":"Saharinen P, Silvennoinen O. The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction. J Biol Chem. 2002;277:47954-47963.","DOI":"10.1074\/jbc.M205156200"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"B10","doi-asserted-by":"crossref","unstructured":"Yan D, Mohi G. Critical Role for Stat5 in the Initiation and Maintenance of Polycythemia Vera in a Jak2V617F Knock-In Mouse Model. Blood (ASH Annual Meeting Abstracts). 2011;118:121.","DOI":"10.1182\/blood.V118.21.121.121"},{"key":"B11","doi-asserted-by":"crossref","unstructured":"Lacout C, Pisani DF, Tulliez M, et al. JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006;108:1652-1660.","DOI":"10.1182\/blood-2006-02-002030"},{"key":"B12","doi-asserted-by":"crossref","unstructured":"Xing S, Wanting T, Zhao W, et al. Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice. Blood. 2008;111:5109-5117.","DOI":"10.1182\/blood-2007-05-091579"},{"key":"B13","doi-asserted-by":"crossref","unstructured":"Chen E, Beer PA, Godfrey AL, et al. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. Cancer Cell. 2010;18:524-535.","DOI":"10.1016\/j.ccr.2010.10.013"},{"key":"B14","doi-asserted-by":"crossref","unstructured":"Delhommeau F, Dupont S, Tonetti C, et al. Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood. 2007;109:71-77.","DOI":"10.1182\/blood-2006-03-007146"},{"key":"B15","doi-asserted-by":"crossref","unstructured":"Jamieson CH, Gotlib J, Durocher JA, et al. The JAK2 V617F mutation occurs in hematopoietic stem cells in polycythemia vera and predisposes toward erythroid differentiation. Proc Natl Acad Sci U S A. 2006;103:6224-6229.","DOI":"10.1073\/pnas.0601462103"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4824"},{"key":"B17","doi-asserted-by":"crossref","unstructured":"Bumm T, Elsea C, Corbin A, et al. Characterization of murine JAK2V617F-positive myeloproliferative disease. Cancer Res. 2006;66:11156-11165.","DOI":"10.1158\/0008-5472.CAN-06-2210"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-12-062125"},{"key":"B19","doi-asserted-by":"crossref","unstructured":"Lambert JR, Everington T, Linch DC, et al. In essential thrombocythemia, multiple JAK2 V617F clones are present in most mutant-positive patients: A new disease paradigm. Blood. 2009;114:3018-3023.","DOI":"10.1182\/blood-2009-03-209916"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22063"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-018879"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2754"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-194548"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-01-198416"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/nature08240"},{"key":"B28","doi-asserted-by":"crossref","unstructured":"Velazquez L, Cheng AM, Fleming HE, et al. Cytokine signaling and hematopoietic homeostasis are disrupted in Lnk-deficient mice. J Exp Med. 2002;195:1599-1611.","DOI":"10.1084\/jem.20011883"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-02-270108"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.163"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1006966"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810069"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-210039"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1126\/science.1170116"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.11.015"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-12-325241"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2011.06.001"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1005143"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.77"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.82"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/ng.1009"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.113"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.12.014"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/ng.621"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.58"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-07-367243"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-06-363424"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/nature08966"},{"key":"B49","doi-asserted-by":"crossref","unstructured":"Gurvich N, Perna F, Farina A, et al. L3MBTL1 polycomb protein, a candidate tumor suppressor in del(20q12) myeloid disorders, is essential for genome stability. Proc Natl Acad Sci U S A. 2010;107:22552-22557.","DOI":"10.1073\/pnas.1017092108"},{"key":"B50","doi-asserted-by":"crossref","unstructured":"Min J, Allali-Hassani A, Nady N, et al. L3MBTL1 recognition of mono- and dimethylated histones. Nat Struct Mol Biol. 2007;14:1229-1230.","DOI":"10.1038\/nsmb1340"},{"key":"B51","doi-asserted-by":"crossref","unstructured":"Perna F, Gurvich N, Hoya-Arias R, et al. Depletion of L3MBTL1 promotes the erythroid differentiation of human hematopoietic progenitor cells: Possible role in 20q- polycythemia vera. Blood. 2010;116:2812-2821.","DOI":"10.1182\/blood-2010-02-270611"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1038\/nature08448"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2010.12.020"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.99"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1012718"},{"key":"B56","doi-asserted-by":"crossref","unstructured":"Silva M, Richard C, Benito A, et al. Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. N Engl J Med. 1998;338:564-571.","DOI":"10.1056\/NEJM199802263380902"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-01-134114"},{"key":"B58","doi-asserted-by":"crossref","unstructured":"Zhao R, Follows GA, Beer PA, et al. Inhibition of the Bcl-xL deamidation pathway in myeloproliferative disorders. N Engl J Med. 2008;359:2778-2789.","DOI":"10.1056\/NEJMoa0804953"},{"key":"B59","doi-asserted-by":"crossref","unstructured":"Capello D, Deambrogi C, Rossi D, et al. Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br J Haematol. 2008;141:504-511.","DOI":"10.1111\/j.1365-2141.2008.07072.x"},{"key":"B60","doi-asserted-by":"crossref","unstructured":"Hookham MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood. 2007;109:4924-4929.","DOI":"10.1182\/blood-2006-08-039735"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/ng.334"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/ng.342"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/ng.341"},{"key":"B64","doi-asserted-by":"crossref","unstructured":"Mead AJ, Rugless MJ, Jacobsen SE, et al. Germline JAK2 mutation in a family with hereditary thrombocytosis. N Engl J Med. 2012;366:967-969.","DOI":"10.1056\/NEJMc1200349"},{"key":"B65","doi-asserted-by":"crossref","unstructured":"Etheridge L, Corbo LM, Kaushansky K, et al. A novel activating JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis (fET) via mechanisms distinct from JAK2V617F. Blood (ASH Annual Meeting Abstracts). 2011;118:123.","DOI":"10.1182\/blood.V118.21.123.123"}],"container-title":["American Society of Clinical Oncology Educational Book"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.14694\/EdBook_AM.2012.32.85","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T07:18:05Z","timestamp":1653808685000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.14694\/EdBook_AM.2012.32.85"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":64,"journal-issue":{"issue":"32","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["10.14694\/EdBook_AM.2012.32.85"],"URL":"https:\/\/doi.org\/10.14694\/edbook_am.2012.32.85","relation":{},"ISSN":["1548-8748","1548-8756"],"issn-type":[{"value":"1548-8748","type":"print"},{"value":"1548-8756","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}